In the Spotlight

• NovaMedica Signs Distribution Agreement with Aptalis Pharma to Develop and Commercialize Gastrointestinal Pharmaceutical Products in Russia

  05 December 2013

  

  NovaMedica LLC, a Russian pharmaceutical company, has signed a partnership agreement with Aptalis Pharma, a leading specialty pharmaceutical company, providing innovative, effective therapies for unmet medical needs, to develop and commercialize a portfolio of three of Aptalis Pharma’s novel gastrointestinal pharmaceutical products in Russia.

• Vladimir Gurdus: With detailed analysis of the Russian market developing NovaMedica’s strategy from scratch has been a unique opportunity for us

  05 November 2013

  

  NovaMedica is expected to launch its first portfolio products in H1 2014 and own developments are expected to launch in 1,5-2 years, - said Vladimir Gurdus, CEO of D-Pharma, Management Company of RusnanoMedInvest LLC and NovaMedica LLC at Pharma Russia Conference hosted by the newspaper “Vedomosti”.

• NovaMedica, Kaluga Region and City of Kaluga Sign Agreement on Construction of Pharmaceutical Plant

  25 July 2013

  

  The Government of Kaluga Region, the Administrative Board of the City of Kaluga and NovaMedica pharmaceutical company have signed an agreement on the execution of an investment project to build a new pharmaceutical plant in the region.

• S.Fyodorov Eye Microsurgery Complex and NovaMedica have signed a cooperation agreement on localizing innovative ophthalmic treatment technologies in Russia

  03 June 2013

  

  S.Fyodorov Eye Microsurgery Complex Federal State Institution and NovaMedica (a pharmaceutical subsidiary of RUSNANO and Domain Associates) have signed an agreement that covers cooperation on localization of innovative ophthalmic products and technologies sourced from around the globe to be developed and produced in Russia. 

• Fabrice Egros has been appointed COO, Pharmaceutical Director and board member of NovaMedica, a novel pharmaceutical company

  12 November 2012

  

  Fabrice Egros was appointed as COO, Pharmaceutical Director and board member of NovaMedica a novel Russian pharmaceutical company, which was established within the frameworks of the joint project between RUSNANO and the American venture fund Domain Associates.